The NCI's MERIT Award extends grant support for Early Stage Investigators up to 7 years, promoting career growth and innovation (NOT-CA-18-037).
Funder: National Institutes of Health
Due Dates: March 1, 2027 (Application) | July 1, 2027 (Application) | November 1, 2027 (Application) | September 7, 2028 (Closing)
Funding Amounts: Budget capped at committed direct costs for the initial award’s final year; extension up to 2 years
Summary: NCI supports a second phase of existing ESI MERIT (R37) awards, providing up to two additional years of cancer research funding.
Key Information: Only currently funded NCI ESI MERIT recipients may request this extension, during their penultimate award year.
The National Cancer Institute (NCI), part of NIH, offers this opportunity for currently funded Early Stage Investigator (ESI) MERIT (R37) recipients to request the second phase of their initial award. The broader MERIT program provides up to seven years of support across two segments, giving investigators flexibility for creativity and innovation and time to establish their careers before submitting renewal applications. Initial conversion to MERIT is based on an ESI’s R01 application receiving a percentile within NCI’s payline for established investigators.
The extension supports work within the original approved project’s scope. NCI’s research goals span cancer causes and prevention, screening and diagnosis, treatment, cancer biology, cancer control, survivorship, and interdisciplinary cancer research. Clinical trials are optional, but requests cannot change the award’s overall human-subjects or clinical-trial designation.